SpectraCure reported a net loss of -12,080 TSEK for H1 2024, with stable EPS and strong equity ratio, while advancing clinical studies for its Q-PRO® prostate cancer treatment system and preparing for broader market entry.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.